Influence of Intravenous Chemotherapy on Cellular Immunity in Patients with Advanced Digestive Tract Cancer
XU Hong1,2, MAO Yi-Xiang1,2, ZHANG Xue-Guang2, WANG Qing-Cai11. Department of Oncology, The First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, 215006, P. R. China 2. Department of Immunology, Institute of Biotechnology, Soochow University, Suzhou, Jiangsu, 215007, P. R. China
BACKGROUND OBJECTIVE: Cancer patients have a poor immune response and chemotherapy could deteriorate their immune system further. Reasonable immune therapy is an important adjuvant remedy for tumors. This study was to monitor the changes of T-cell phenotypes in peripheral blood and interleukin-2 (IL-2) concentration in plasma in digestive tract cancer patients before and after chemotherapy. METHODS: The proportions of CD3+, CD4+, CD8+, CD4+CD28+, CD8+CD28+ and CD4+CD25+ T cells in peripheral blood of 104 patients with advanced digestive tract cancer, hospitalized from Sep. 2005 to Apr. 2006, were detected by flow cytometry (FCM). The concentration of IL-2 in plasma was measured by ELISA. RESULTS: The proportions of CD4+, CD4+CD28+, CD8+CD28+, CD4+CD25+ T cells and ratio of CD4/CD8 were (36.52±3.85)%, (32.87±4.98)%, (6.87±3.11)%, (9.68±3.42)% and 0.98±0.17 in digestive tract cancer patients, and (45.23±9.20)%, (40.12±5.85)%, (15.8±4.50)%, (5.67±2.90)% and 1.43±0.12 in healthy subjects. In the patients with response to chemotherapy, the proportions of CD4+CD28+ and CD8+CD28+ T cells and ratio of CD4/CD8 were (22.93±3.98)%, (7.08±1.23)% and 0.90±0.22 before chemotherapy, and (28.25±4.03)%, (12.10±3.45)% and 1.24±0.22 at 3 weeks after chemotherapy. In the patients with no response to chemotherapy, the proportions of CD4+CD28+, CD8+CD28+ and CD4+CD25+ T cells were (24.08±4.02)%, (6.35±1.23)% and (8.20±2.34)% before chemotherapy, and (16.45±3.27)%, (3.20±0.82)% and (20.34±3.69)% at 3 weeks after chemotherapy. CONCLUSIONS: The immunosuppression of digestive tract cancer patients would be enhanced early (about 1-2 weeks) after intravenous chemotherapy. The immunity of the patients with response to chemotherapy would be improved at 3 weeks after chemotherapy; while the immunity of the patients with no response to chemotherapy would not change, or even be suppressed.
【CateGory Index】： R735